Does the media favor XNCR or RYTM?

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat Rhythm Pharmaceuticals' score of 0.63 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, SRRK or XNCR?

Xencor has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A Xencor $125.58M 14.45 -$91.92M -$2.17 N/A

Is SRRK or XNCR more profitable?

Scholar Rock has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Xencor -155.59% -28.66% -20.38%

Does the media refer more to SRRK or XNCR?

In the previous week, Scholar Rock had 8 more articles in the media than Xencor. MarketBeat recorded 12 mentions for Scholar Rock and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat Scholar Rock's score of 0.71 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, XNCR or CGON?

Xencor has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 14.45 -$91.92M -$2.17 N/A CG Oncology $4.04M 1,587.40 -$160.99M -$2.69 N/A

Is XNCR or CGON more profitable?

Xencor has a net margin of -155.59% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -155.59% -28.66% -20.38% CG Oncology -3,602.68% -25.20% -23.98%

Does the media favor XNCR or CGON?

In the previous week, CG Oncology had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for CG Oncology and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat CG Oncology's score of 1.35 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, XNCR or MIRM?

Mirum Pharmaceuticals has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 14.45 -$91.92M -$2.17 N/A Mirum Pharmaceuticals $521.31M 12.23 -$23.36M -$14.55 N/A

Does the media favor XNCR or MIRM?

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat Mirum Pharmaceuticals' score of 0.42 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor XNCR or ORKA?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Xencor. MarketBeat recorded 7 mentions for Oruka Therapeutics and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat Oruka Therapeutics' score of -0.07 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Xencor (XNCR) Competitors

$24.41 +0.15 (+0.62%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$24.68 +0.27 (+1.11%)

As of 09/11/2026 07:30 PM Eastern

Compare

XNCR vs. RYTM, SRRK, CGON, MIRM, and ORKA

Should you buy Xencor stock or one of its competitors? Xencor's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), and Oruka Therapeutics (ORKA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xencor compare to Rhythm Pharmaceuticals?

Xencor (NASDAQ:XNCR) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat Rhythm Pharmaceuticals' score of 0.63 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market.

Xencor presently has a consensus target price of $31.86, suggesting a potential upside of 30.51%. Rhythm Pharmaceuticals has a consensus target price of $141.12, suggesting a potential upside of 34.77%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

Xencor has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	14.45	-$91.92M	-$2.17	N/A
Rhythm Pharmaceuticals	$189.76M	37.82	-$196.54M	-$3.11	N/A

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Summary

Rhythm Pharmaceuticals beats Xencor on 8 of the 15 factors compared between the two stocks.

How does Xencor compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Scholar Rock has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Xencor	-155.59%	-28.66%	-20.38%

Scholar Rock presently has a consensus price target of $58.77, suggesting a potential upside of 6.06%. Xencor has a consensus price target of $31.86, suggesting a potential upside of 30.51%. Given Xencor's higher possible upside, analysts plainly believe Xencor is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06
Xencor	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Scholar Rock had 8 more articles in the media than Xencor. MarketBeat recorded 12 mentions for Scholar Rock and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat Scholar Rock's score of 0.71 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Xencor has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 5.1% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Xencor has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Xencor	$125.58M	14.45	-$91.92M	-$2.17	N/A

Summary

Xencor beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Xencor compare to CG Oncology?

Xencor (NASDAQ:XNCR) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Xencor presently has a consensus target price of $31.86, indicating a potential upside of 30.51%. CG Oncology has a consensus target price of $87.78, indicating a potential upside of 21.32%. Given Xencor's higher possible upside, equities analysts clearly believe Xencor is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Xencor has a net margin of -155.59% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, CG Oncology had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for CG Oncology and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat CG Oncology's score of 1.35 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	14.45	-$91.92M	-$2.17	N/A
CG Oncology	$4.04M	1,587.40	-$160.99M	-$2.69	N/A

26.6% of CG Oncology shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xencor has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

Xencor beats CG Oncology on 11 of the 17 factors compared between the two stocks.

How does Xencor compare to Mirum Pharmaceuticals?

Xencor (NASDAQ:XNCR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Mirum Pharmaceuticals has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	14.45	-$91.92M	-$2.17	N/A
Mirum Pharmaceuticals	$521.31M	12.23	-$23.36M	-$14.55	N/A

Mirum Pharmaceuticals has a net margin of -139.18% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat Mirum Pharmaceuticals' score of 0.42 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Xencor currently has a consensus price target of $31.86, indicating a potential upside of 30.51%. Mirum Pharmaceuticals has a consensus price target of $137.31, indicating a potential upside of 39.80%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Xencor has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Xencor on 9 of the 14 factors compared between the two stocks.

How does Xencor compare to Oruka Therapeutics?

Xencor (NASDAQ:XNCR) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Xencor has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Xencor. MarketBeat recorded 7 mentions for Oruka Therapeutics and 4 mentions for Xencor. Xencor's average media sentiment score of 1.39 beat Oruka Therapeutics' score of -0.07 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Oruka Therapeutics' return on equity of -21.65% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Xencor presently has a consensus target price of $31.86, indicating a potential upside of 30.51%. Oruka Therapeutics has a consensus target price of $133.00, indicating a potential upside of 43.97%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

56.4% of Oruka Therapeutics shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Xencor has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	14.45	-$91.92M	-$2.17	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Summary

Oruka Therapeutics beats Xencor on 9 of the 16 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XNCR vs. The Competition

Export

Metric	Xencor	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.81B	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-11.25	14.18	274.94	25.33
Price / Sales	14.45	1,375.01	685.45	111.12
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	2.74	15.12	10.33	6.20
Net Income	-$91.92M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-8.27%	-4.34%	-3.32%	-2.35%
1 Month Performance	5.31%	-0.02%	-0.41%	-2.77%
1 Year Performance	183.84%	40.64%	19.21%	7.63%

Xencor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XNCR Xencor	2.5603 of 5 stars	$24.41 +0.6%	$31.86 +30.5%	+183.8%	$1.81B	$125.58M	N/A	260	Positive News Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.5613 of 5 stars	$102.27 -0.5%	$141.12 +38.0%	+8.8%	$7.01B	$189.76M	N/A	140	Positive News Gap Down
SRRK Scholar Rock	1.812 of 5 stars	$57.13 +3.3%	$58.77 +2.9%	+75.0%	$6.96B	N/A	N/A	140	News Coverage Analyst Forecast
CGON CG Oncology	3.1647 of 5 stars	$74.25 -0.6%	$87.78 +18.2%	+117.0%	$6.58B	$4.04M	N/A	61	Positive News Options Volume
MIRM Mirum Pharmaceuticals	2.7522 of 5 stars	$100.87 0.0%	$137.31 +36.1%	+32.2%	$6.53B	$521.31M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XNCR) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xencor (XNCR) Competitors

XNCR vs. RYTM, SRRK, CGON, MIRM, and ORKA

How does Xencor compare to Rhythm Pharmaceuticals?

Summary

How does Xencor compare to Scholar Rock?

Summary

How does Xencor compare to CG Oncology?

Summary

How does Xencor compare to Mirum Pharmaceuticals?

Summary

How does Xencor compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xencor (XNCR) Competitors

XNCR vs. RYTM, SRRK, CGON, MIRM, and ORKA

How does Xencor compare to Rhythm Pharmaceuticals?

Does the media favor XNCR or RYTM?

Which has more risk & volatility, XNCR or RYTM?

Do analysts recommend XNCR or RYTM?

Which has better earnings & valuation, XNCR or RYTM?

Is XNCR or RYTM more profitable?

Summary

How does Xencor compare to Scholar Rock?

Is SRRK or XNCR more profitable?

Do analysts recommend SRRK or XNCR?

Does the media refer more to SRRK or XNCR?

Which has more volatility and risk, SRRK or XNCR?

Do institutionals and insiders believe in SRRK or XNCR?

Which has higher valuation & earnings, SRRK or XNCR?

Summary

How does Xencor compare to CG Oncology?

Do analysts prefer XNCR or CGON?

Is XNCR or CGON more profitable?

Does the media favor XNCR or CGON?

Which has higher valuation and earnings, XNCR or CGON?

Do institutionals and insiders believe in XNCR or CGON?

Which has more risk and volatility, XNCR or CGON?

Summary

How does Xencor compare to Mirum Pharmaceuticals?

Which has higher earnings and valuation, XNCR or MIRM?

Is XNCR or MIRM more profitable?

Does the media favor XNCR or MIRM?

Do analysts recommend XNCR or MIRM?

Which has more risk and volatility, XNCR or MIRM?

Summary

How does Xencor compare to Oruka Therapeutics?

Which has more volatility and risk, XNCR or ORKA?

Does the media favor XNCR or ORKA?

Is XNCR or ORKA more profitable?

Do analysts recommend XNCR or ORKA?

Do insiders & institutionals believe in XNCR or ORKA?

Which has preferable valuation and earnings, XNCR or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools